m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02970)
Name
BRD9539
Synonyms
BRD-9539; BRD 9539
    Click to Show/Hide
Status
Investigative
Structure
Formula
C24H21N3O3
InChI
1S/C24H21N3O3/c28-22(18-11-5-2-6-12-18)26-24-25-20-16-19(23(29)30)13-14-21(20)27(24)15-7-10-17-8-3-1-4-9-17/h1-6,8-9,11-14,16H,7,10,15H2,(H,29,30)(H,25,26,28)
InChIKey
WPXMEOBILYVKBC-UHFFFAOYSA-N
PubChem CID
73755260
TTD Drug ID
D0RO9T
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Histone-lysine N-methyltransferase EHMT2 (EHMT2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Histone-lysine N-methyltransferase EHMT2 (EHMT2) is a therapeutic target for BRD9539. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BRD9539 through regulating the expression of Histone-lysine N-methyltransferase EHMT2 (EHMT2). [1], [2]
References
Ref 1 N(6)-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons. Adv Sci (Weinh). 2020 May 27;7(13):1902402. doi: 10.1002/advs.201902402. eCollection 2020 Jul.
Ref 2 Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9. doi: 10.1021/ml400496h. eCollection 2014 Feb 13.